According to the latest studies, the first vaccine against Covid-19 inhalable -developed by CanSino Biologics– it turned out to be effective and safe when applied as a reinforcement, with an increase in 250 to 300 times in antibody levels.
“Laboratory studies showed that the inhalable vaccine against COVID-19 (Ad5-nCoV) Adenovirus type 5 aerosol, given six months after completing two doses of injections, is safe and significantly more immunogenic than receiving an inactivated vaccine as a booster“said Zhu Tao, Co-Founder and Chief Scientific Officer of CanSinoBIO, at an industry conference.
To verify its effectiveness, the aerosol was tested in people who had received two doses of vaccines previously, which could mean an effective alternative for the combination of different types of vaccines.
Homogeneous and heterogeneous
Clinical trials suggested that a heterogeneous combination (inhalable and injectable) may increase the intensity and duration of the immune response, more than a booster regimen homogeneous.
Notably, US researchers had previously conducted booster clinical trials with a vaccination regimen heterogeneous, with three approved vaccines: Johnson & Johnson -denovirus- and two mRNA vaccines of Modern and Pfizer.
These results also showed similarly that the immunity achieved in these tests was more effective. CanSinoBIO researchers estimate that, if approved Chinese vaccines are combined in a heterogeneous booster regimen, the most effective response in the whole world could be achieved.
– .
